The receptors of the moment, however, and of broadest societal relevance, are the incretin hormone receptors, GLP1R and GIPR—both key targets for anti-obesity therapy development24. The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.